101 |
NCT02627443 |
Recruiting |
Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
- High Grade Ovarian Serous Adenocarcinoma
- Ovarian Endometrioid Tumor
- Recurrent Fallopian Tube Carcinoma
- (and 5 more...)
|
- Drug: ATR Kinase Inhibitor VX-970
- Drug: Carboplatin
- Drug: Gemcitabine Hydrochloride
- (and 2 more...)
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- OS
- Confirmed response rate per RECIST 1.1 criteria
- Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
|
150 |
Female |
18 Years and older (Adult, Senior) |
NCT02627443 |
NCI-2015-02064 MC1563 9948 N01CM00099 P30CA015083 UM1CA186686 |
|
November 4, 2016 |
November 30, 2020 |
|
December 11, 2015 |
March 19, 2018 |
|
- Mayo Clinic Hospital
Phoenix, Arizona, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - Mayo Clinic
Rochester, Minnesota, United States
|
102 |
NCT00003865 |
Withdrawn |
Toremifene in Treating Patients With Ovarian Cancer |
|
|
Interventional |
Phase 2 |
- George Washington University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
0 |
Female |
18 Years to 120 Years (Adult, Senior) |
NCT00003865 |
GWCC-7096 CDR0000067029 NCI-V99-1540 |
|
July 22, 1999 |
February 22, 2017 |
February 22, 2017 |
January 27, 2003 |
July 13, 2017 |
|
- George Washington University Cancer Center
Washington, D.C., District of Columbia, United States
|
103 |
NCT00275028 |
Completed Has Results |
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer |
- Fallopian Tube Cancer
- Primary Peritoneal Serous Adenocarcinoma
- Recurrent Ovarian Epithelial Cancer
- (and 2 more...)
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Response Benefit (Modified Gynecologic Cancer InterGroup [GCIG] Cancer Antigen [CA]-125 Response or Stable Disease) Based on the Response Evaluation Criteria in Solid Tumors (RECIST)
- Progression-free Survival
|
47 |
Female |
18 Years and older (Adult, Senior) |
NCT00275028 |
NCI-2013-00036 05-170 U01CA062490 |
|
October 2005 |
March 2010 |
January 2011 |
January 11, 2006 |
November 9, 2015 |
November 9, 2015 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
104 |
NCT00005840 |
Completed |
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer |
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Stage III Uterine Corpus Cancer
- Stage IV Uterine Corpus Cancer
|
- Drug: Paclitaxel
- Drug: Cisplatin
- Radiation: Radiation Therapy
|
Interventional |
Phase 1 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Acute toxicity for identification of MTD, using the 21 major categories of the Cancer Therapy Evaluation Program Common Toxicity Criteria (CTEP CTC) v2.0
- Chronic toxicity based on the NCI CTC Radiation Therapy Oncology Group (RTOG)/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity scoring scheme
- Number of dose level combinations that will have been evaluated prior to MTD establishment
- Site (local/distant) of treatment failure
|
35 |
Female |
18 Years and older (Adult, Senior) |
NCT00005840 |
GOG-9907 NCI-2012-02334 CDR0000067856 U10CA027469 |
|
July 2000 |
July 2009 |
|
January 27, 2003 |
December 31, 2014 |
|
- Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
|
105 |
NCT02834169 |
Active, not recruiting |
French National Registry of Rare Peritoneal Surface Malignancies |
- Rare Peritoneal Surface Malignancies
- Pseudomyxoma Peritonei
- Peritoneal Mesothelioma
- (and 5 more...)
|
- Other: Non interventional
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Incidence of rare peritoneal surface malignancies
- Impact of specific treatment strategies
|
2171 |
All |
Child, Adult, Senior |
NCT02834169 |
69HCL16_0406 |
RENAPE |
October 2010 |
December 2018 |
December 2018 |
July 15, 2016 |
August 22, 2017 |
|
- Institut de Cancérologie de l'Ouest - Paul Papin
Angers, France - CHU Jean Minjoz
Besancon, France - Institut Bergonié
Bordeaux, France - (and 30 more...)
|
106 |
NCT02874430 |
Recruiting |
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer |
- Breast Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- (and 2 more...)
|
- Drug: Metformin Hydrochloride
- Drug: Doxycycline
|
Interventional |
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the percent of stromal cells expressing Caveolin-1 (CAV1) at an intensity of 1+ or greater assessed by immunohistochemistry
- Incidence of adverse events evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Change in the percent of stromal cells expressing express Monocarboxylate Transporter 4 (MCT4) in the cancer cells
- (and 6 more...)
|
46 |
Female |
18 Years and older (Adult, Senior) |
NCT02874430 |
16D.317 |
|
June 8, 2016 |
February 2021 |
January 2022 |
August 22, 2016 |
March 16, 2018 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
107 |
NCT01132820 |
Completed Has Results |
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer |
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- (and 2 more...)
|
- Drug: Cediranib Maleate
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0
- Tumor Response
- Progression-free Survival (PFS) = > 6 Months
- (and 3 more...)
|
53 |
Female |
18 Years and older (Adult, Senior) |
NCT01132820 |
NCI-2011-02043 GOG-0229J CDR0000674008 U10CA180868 U10CA027469 |
|
June 2010 |
January 2016 |
January 2016 |
May 28, 2010 |
August 28, 2017 |
August 28, 2017 |
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, United States - Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California, United States - Hartford Hospital
Hartford, Connecticut, United States - (and 84 more...)
|
108 |
NCT02756130 |
Not yet recruiting |
Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- High Grade Fallopian Tube Serous Adenocarcinoma
- High Grade Ovarian Serous Adenocarcinoma
- Primary Peritoneal High Grade Serous Adenocarcinoma
- (and 3 more...)
|
- Drug: Birinapant
- Drug: Carboplatin
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional |
Phase 1 Phase 2 |
- Jonsson Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in percentage of cancer initiating cells
- Pharmacodynamic analysis of cellular inhibitor of apoptosis (cIAP) protein
- Progression free survival (PFS) assessed using imaging (multiparametric magnetic resonance imaging [MRI] (primary modality of imaging) of computed tomography (CT) and the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
|
17 |
Female |
18 Years and older (Adult, Senior) |
NCT02756130 |
16-000746 NCI-2016-00596 GODL001 P30CA016042 |
|
April 1, 2018 |
February 1, 2020 |
February 1, 2021 |
April 29, 2016 |
February 21, 2018 |
|
- UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
|
109 |
NCT01935973 |
Active, not recruiting |
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer |
- Endometrial Adenocarcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Mixed Adenocarcinoma
- (and 3 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Trametinib
- Drug: Uprosertib
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS by regimen administered using RECIST version 1.1 (Phase II)
- Frequency of adverse events defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related
- Severity of adverse events, graded using the NCI CTCAE version 4.0 (Safety assessment and phase II)
- (and 7 more...)
|
26 |
Female |
18 Years and older (Adult, Senior) |
NCT01935973 |
NCI-2013-01659 GOG-0229O P50CA098258 U10CA180868 U10CA027469 |
|
September 30, 2013 |
February 1, 2017 |
|
September 5, 2013 |
March 23, 2018 |
|
- Hartford Hospital
Hartford, Connecticut, United States - The Hospital of Central Connecticut
New Britain, Connecticut, United States - Augusta University Medical Center
Augusta, Georgia, United States - (and 19 more...)
|
110 |
NCT02065687 |
Active, not recruiting |
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer |
- Endometrial Adenocarcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- (and 9 more...)
|
- Drug: Carboplatin
- Other: Laboratory Biomarker Analysis
- Drug: Metformin Hydrochloride
- (and 4 more...)
|
Interventional |
Phase 2 Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS) (Phase II)
- Overall survival (OS) (Phase II and III)
- Proportion of patients responding to therapy
- (and 5 more...)
|
540 |
Female |
18 Years and older (Adult, Senior) |
NCT02065687 |
GOG-0286B NCI-2013-02284 s14-01068 U10CA180830 U10CA180868 U10CA027469 |
|
March 17, 2014 |
September 1, 2019 |
|
February 19, 2014 |
March 9, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Tennessee Valley Gynecologic Oncology
Huntsville, Alabama, United States - University of Arizona Cancer Center at Saint Joseph's
Phoenix, Arizona, United States - (and 430 more...)
|
111 |
NCT02345265 |
Active, not recruiting |
Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- Fallopian Tube Endometrioid Adenocarcinoma
- (and 7 more...)
|
- Drug: Cediranib Maleate
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
- (and 2 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Objective response rate, defined as confirmed complete response or partial response under Response Evaluation Criteria in Solid Tumors 1.1 (platinum-resistant cohort)
- Biomarker signature development
- (and 4 more...)
|
70 |
Female |
18 Years and older (Adult, Senior) |
NCT02345265 |
NCI-2015-00051 16-700 9825 UM1CA186644 UM1CA186686 UM1CA186690 UM1CA186691 UM1CA186704 UM1CA186709 UM1CA186712 UM1CA186716 UM1CA186717 ZIABC011078 |
|
December 4, 2015 |
February 1, 2019 |
|
January 26, 2015 |
March 5, 2018 |
|
- Mayo Clinic Hospital
Phoenix, Arizona, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - City of Hope Comprehensive Cancer Center
Duarte, California, United States - (and 17 more...)
|
112 |
NCT02315469 |
Active, not recruiting |
Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery |
- Endometrial Serous Adenocarcinoma
- Fallopian Tube Carcinoma
- Ovarian Carcinoma
- (and 6 more...)
|
- Other: Comprehensive Geriatric Assessment
- Other: Questionnaire Administration
|
Observational |
|
- NRG Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
|
- GA-GYN score, defined as the summation of the risk score for each risk factor derived from the predictive model including 5 risk factors from the GA and 3 other risk factors
- Occurrence of major post-operative complications outlined in The American College of Surgeons? National Surgical Quality Improvement Program
- Comorbidity, as measured by the Older American Resources and Services (OARS) Physical Health section
- (and 11 more...)
|
190 |
Female |
70 Years and older (Senior) |
NCT02315469 |
NRG-CC002 NCI-2014-01376 GOG-ELD1301 U10CA101165 UG1CA189867 |
|
February 10, 2015 |
March 15, 2016 |
|
December 11, 2014 |
February 16, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - (and 390 more...)
|
113 |
NCT01005329 |
Completed Has Results |
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer |
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- (and 9 more...)
|
- Biological: Bevacizumab
- Drug: Carboplatin
- Drug: Cisplatin
- (and 2 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- Radiation Therapy Oncology Group
|
NIH / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Treatment-related, Grade 3+, Non-hematologic Adverse Events Occuring Within 90 Days After Treatment Start
- Percentage of Participants With Treatment-related, Grade 3+, Non-hematologic Adverse Events Occuring Within 1 Year After Treatment Start
- Treatment-related Grade 3+ Adverse Events
- (and 4 more...)
|
34 |
Female |
18 Years and older (Adult, Senior) |
NCT01005329 |
NCI-2011-01982 CDR0000657979 RTOG-0921 RTOG 0921 U10CA021661 |
|
November 6, 2009 |
June 30, 2012 |
September 22, 2013 |
October 30, 2009 |
March 15, 2018 |
February 24, 2014 |
- Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States - John Muir Medical Center-Walnut Creek
Walnut Creek, California, United States - Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, United States - (and 38 more...)
|
114 |
NCT01306032 |
Completed Has Results |
Phase II ABT-888 With Cyclophosphamide |
- Ovarian Cancer
- Primary Peritoneal Cancer
- Serous Carcinoma Cancer
- (and 2 more...)
|
- Drug: ABT-888
- Drug: Cyclophosphamide
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With an Overall Response Rate
- Progression Free Survival
- Number of Participants With Adverse Events
- (and 3 more...)
|
124 |
All |
18 Years and older (Adult, Senior) |
NCT01306032 |
110080 11-C-0080 |
|
January 12, 2011 |
December 31, 2014 |
December 15, 2016 |
March 1, 2011 |
April 26, 2017 |
May 25, 2016 |
- University of California, Davis
Davis, California, United States - H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States - University of Chicago
Chicago, Illinois, United States - (and 7 more...)
|
115 |
NCT00807768 |
Active, not recruiting |
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer |
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Fatigue
- (and 4 more...)
|
- Radiation: 3-Dimensional Conformal Radiation Therapy
- Drug: Carboplatin
- Radiation: Intensity-Modulated Radiation Therapy
- (and 5 more...)
|
Interventional |
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Duration of recurrence-free survival
- Contributing cause of death
- Cumulative incidence of extra-pelvic recurrence
- (and 2 more...)
|
595 |
Female |
18 Years and older (Adult, Senior) |
NCT00807768 |
GOG-0249 NCI-2009-00610 CDR0000629591 U10CA180868 U10CA027469 |
|
March 2009 |
December 2014 |
|
December 12, 2008 |
May 8, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 510 more...)
|
116 |
NCT01167725 |
Unknown † |
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer |
|
- Biological: bevacizumab
- Biological: cetuximab
- Drug: FOLFIRI regimen
- (and 8 more...)
|
Interventional |
Phase 3 |
- Walter Reed Army Medical Center
- National Cancer Institute (NCI)
|
U.S. Fed / NIH |
- Allocation: Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Progression-free survival (PFS)
- Quality of life
- (and 3 more...)
|
340 |
All |
18 Years and older (Adult, Senior) |
NCT01167725 |
CDR0000681540 WRAMC-8214 |
|
August 2010 |
May 2014 |
|
July 22, 2010 |
January 24, 2012 |
|
- St. Agnes Hospital Cancer Center
Baltimore, Maryland, United States - Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
|
117 |
NCT03422198 |
Recruiting |
Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer |
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- (and 6 more...)
|
- Radiation: Vaginal Cuff Brachytherapy
- Radiation: Short course vaginal cuff brachytherapy
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Health related quality of life (HRQOL) using the Global Health Score from the Quality of Life Questionnaire Core 30 (QLQ-C30)
- Treatment-related symptoms on HRQOL using European Organization for Research and Treatment of Cancer Endometrial Cancer Module (EORTC EN24), question 48
- Cost effectiveness (CE)
|
108 |
All |
Child, Adult, Senior |
NCT03422198 |
HCI103841 NCI-2018-00011 |
SAVE |
January 17, 2018 |
January 8, 2022 |
January 8, 2022 |
February 5, 2018 |
April 19, 2018 |
|
- Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States
|
118 |
NCT03120624 |
Recruiting |
VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer |
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Mixed Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- (and 8 more...)
|
- Procedure: Biopsy
- Procedure: Computed Tomography
- Other: Laboratory Biomarker Analysis
- (and 5 more...)
|
Interventional |
Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of adverse events graded according to the NCI CTCAE version 4
- Maximum tolerated dose of VSV-hIFNbeta-NIS graded according to the National Cancer Institute (NCI) CTCAE version 4
- Biodistribution and kinetics of virus spread and NIS gene expression in vivo assessed via SPECT/CT
- (and 4 more...)
|
33 |
Female |
18 Years and older (Adult, Senior) |
NCT03120624 |
MC1562 NCI-2017-00615 P30CA015083 |
|
September 15, 2017 |
June 2019 |
June 2019 |
April 19, 2017 |
March 15, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
119 |
NCT02898207 |
Recruiting |
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer |
- Estrogen Receptor Negative
- HER2/Neu Negative
- High Grade Fallopian Tube Serous Adenocarcinoma
- (and 10 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
- Drug: Onalespib
- Other: Pharmacological Study
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose defined as the highest dose at which 0 of 3 or 1 of 6 or fewer patients experience a dose-limiting toxicity
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02898207 |
NCI-2016-01364 17-715 10031 UM1CA186709 |
|
May 19, 2017 |
June 1, 2020 |
June 1, 2020 |
September 13, 2016 |
April 3, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States - (and 4 more...)
|
120 |
NCT02713386 |
Recruiting |
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Serous Neoplasm
- (and 19 more...)
|
- Drug: Carboplatin
- Other: Laboratory Biomarker Analysis
- Drug: Paclitaxel
- (and 2 more...)
|
Interventional |
Phase 1 Phase 2 |
- NRG Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of hematologic (heme) dose-limiting toxicity assessed according to Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Phase I)
- Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Phase II)
- Complete pathological response, defined as no evidence of disease on radiographic imaging at the time of radiographic tumor measurement (Phase II)
- (and 5 more...)
|
162 |
Female |
18 Years and older (Adult, Senior) |
NCT02713386 |
NRG-GY007 NCI-2016-00203 U10CA180868 |
|
May 18, 2016 |
September 30, 2020 |
|
March 18, 2016 |
February 16, 2018 |
|
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States - University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States - (and 8 more...)
|
121 |
NCT02839707 |
Recruiting |
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- High Grade Fallopian Tube Serous Adenocarcinoma
- (and 10 more...)
|
- Drug: Atezolizumab
- Biological: Bevacizumab
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional |
Phase 2 Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose limiting toxicities (DLT) of experimental regimens graded using Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0 (CTCAE version 5.0 will be used beginning April 1, 2018)
- Progression free survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria (Phase II)
- Overall survival (OS) (Phase III)
- (and 10 more...)
|
488 |
Female |
18 Years and older (Adult, Senior) |
NCT02839707 |
NCI-2016-01081 NRG-GY009 U10CA180868 UG1CA189867 |
|
May 12, 2017 |
June 30, 2023 |
June 30, 2023 |
July 21, 2016 |
April 20, 2018 |
|
- University of Colorado Hospital
Aurora, Colorado, United States - Augusta University Medical Center
Augusta, Georgia, United States - John H Stroger Jr Hospital of Cook County
Chicago, Illinois, United States - (and 17 more...)
|
122 |
NCT02627430 |
Withdrawn |
Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer |
- Adult Solid Neoplasm
- Estrogen Receptor Negative
- Fallopian Tube Serous Neoplasm
- (and 10 more...)
|
- Drug: Hsp90 Inhibitor AT13387
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: Talazoparib
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD based on the dose-limiting toxicity based on the National Cancer Institute (NCI) CTCAE v. 4.0
- Incidence of adverse events as assessed by NCI CTCAE v. 4.0
- Pharmacokinetic (PK) parameters of talazoparib and HSP90 inhibitor AT13387
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT02627430 |
NCI-2015-02063 9896 P30CA006516 UM1CA186709 |
|
March 2016 |
March 2019 |
|
December 11, 2015 |
July 26, 2016 |
|
|
123 |
NCT02502266 |
Suspended |
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- Fallopian Tube Clear Cell Adenocarcinoma
- (and 14 more...)
|
- Drug: Cediranib Maleate
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
- (and 4 more...)
|
Interventional |
Phase 2 Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (Phase II and Phase III)
- Overall survival (Phase III)
- Objective response rate (partial or complete response), defined by Response Evaluation Criteria in Solid Tumors version 1.1 criteria (Phase II and Phase III)
- Incidence of adverse events (Phase II and Phase III)
|
680 |
Female |
18 Years and older (Adult, Senior) |
NCT02502266 |
NCI-2015-00651 s16-01681 NRG-GY005 U10CA180868 |
|
February 5, 2016 |
June 30, 2023 |
|
July 20, 2015 |
April 12, 2018 |
|
- Alaska Women's Cancer Care
Anchorage, Alaska, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - (and 271 more...)
|
124 |
NCT02364713 |
Recruiting |
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer |
- Fallopian Tube Transitional Cell Carcinoma
- Malignant Ovarian Clear Cell Tumor
- Malignant Ovarian Endometrioid Tumor
- (and 9 more...)
|
- Drug: Gemcitabine Hydrochloride
- Other: Laboratory Biomarker Analysis
- Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- (and 4 more...)
|
Interventional |
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Incidence of adverse events per Common Terminology Criteria for Adverse Events version 4.0
- Objective response rates defined to be a complete response or partial response noted as the objective status on 2 consecutive evaluations at least 4 weeks apart
- (and 2 more...)
|
134 |
Female |
18 Years and older (Adult, Senior) |
NCT02364713 |
MC1365 NCI-2015-00133 P30CA015083 |
|
March 2015 |
February 2025 |
February 2025 |
February 18, 2015 |
April 21, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
125 |
NCT02016833 |
Completed |
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity |
- Ovarian Serous Adenocarcinoma
- Undifferentiated Carcinoma of Ovary
- Cervical Cancer
- (and 3 more...)
|
- Procedure: Blood Sampling
|
Observational |
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- Development and validation of ELISpot and tetramer assays for the detection of tumor-antigen specific T cell immune responses in cancer patients
- Characterisation of WT1, Survivin and HPV16 E7 specific immune responses in cancer patients
|
15 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02016833 |
PX_DCtagTM_LeadIn_001 |
|
October 2013 |
June 2014 |
December 2014 |
December 20, 2013 |
April 30, 2015 |
|
- Peter MacCallum Cancer Center
Melbourne, Victoria, Australia
|
126 |
NCT01307631 |
Completed Has Results |
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer |
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- (and 2 more...)
|
- Drug: Akt Inhibitor MK2206
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Tumor Response According to RECIST
- Progression-free Survival According to RECIST
- Duration of Overall Survival
- Duration of Progression-free Survival
|
37 |
Female |
18 Years and older (Adult, Senior) |
NCT01307631 |
NCI-2013-00521 10.258 10-258 8760 P30CA006516 U01CA062490 UM1CA186709 |
|
March 2011 |
January 2016 |
June 30, 2017 |
March 3, 2011 |
September 5, 2017 |
September 5, 2017 |
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - (and 4 more...)
|
127 |
NCT01935934 |
Suspended |
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer |
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Mixed Adenocarcinoma
- (and 7 more...)
|
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Progression-free survival
- Baseline molecular status of archival tumor (c-met amplification and mutation status)
- (and 2 more...)
|
72 |
Female |
18 Years and older (Adult, Senior) |
NCT01935934 |
NCI-2013-00890 PHL-086 9322 N01CM00032 N01CM00038 N01CM00071 UM1CA186644 |
|
April 29, 2013 |
March 31, 2019 |
|
September 5, 2013 |
April 18, 2018 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - (and 17 more...)
|
128 |
NCT01210222 |
Completed Has Results |
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer |
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- (and 4 more...)
|
|
Interventional |
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free Survival > 6 Months
- Objective Tumor Response (Complete or Partial Response)
- Adverse Events as Assessed by NCI CTCAE v 4.0
- (and 2 more...)
|
35 |
Female |
18 Years and older (Adult, Senior) |
NCT01210222 |
GOG-0229L NCI-2011-02655 CDR0000686066 U10CA180868 U10CA027469 |
|
June 6, 2011 |
July 16, 2016 |
July 16, 2016 |
September 28, 2010 |
February 23, 2018 |
November 29, 2017 |
- Hartford Hospital
Hartford, Connecticut, United States - The Hospital of Central Connecticut
New Britain, Connecticut, United States - Sarasota Memorial Hospital
Sarasota, Florida, United States - (and 30 more...)
|
129 |
NCT00977574 |
Active, not recruiting Has Results |
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer |
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- (and 7 more...)
|
- Biological: Bevacizumab
- Drug: Carboplatin
- Drug: Ixabepilone
- (and 3 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants Who Progressed or Died by 25 Months From Enrollment
- Frequency and Severity of Toxicity as Assessed by CTCAE v3.0 for Each of the Three Arms.
- The Median Duration of Overall Survival for Each of the Three Arms.
- The Proportion of Patients With Measurable Disease Who Have Confirmed Objective Tumor Responses by Treatment.
|
349 |
Female |
18 Years and older (Adult, Senior) |
NCT00977574 |
NCI-2011-01969 CDR0000654472 GOG-0086P U10CA180868 U10CA027469 |
|
September 2009 |
January 2017 |
September 2021 |
September 15, 2009 |
February 27, 2018 |
February 27, 2018 |
- Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States - (and 228 more...)
|
130 |
NCT01116648 |
Active, not recruiting |
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer |
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- Estrogen Receptor Negative
- (and 10 more...)
|
- Drug: Cediranib Maleate
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
- Other: Pharmacological Study
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose limiting toxicity and maximum tolerated dose of cediranib maleate in combination with olaparib (Phase I)
- Progression-free survival at the maximum tolerated dose/recommended phase 2 dose of cediranib maleate with olaparib compared to that of olaparib alone (Phase II)
- Dose limiting toxicities and maximum tolerated dose of cediranib maleate in combination with olaparib (tablet formulation) (Phase I-Tablet)
- (and 5 more...)
|
162 |
Female |
18 Years and older (Adult, Senior) |
NCT01116648 |
NCI-2012-02938 DFCI IRB 09-293 NCI-2010-01329 NCI-2013-00578 8348 N01CM00071 P30CA006516 U01CA062490 UM1CA186709 |
|
March 25, 2010 |
October 31, 2018 |
|
May 5, 2010 |
March 5, 2018 |
|
- Cedars Sinai Medical Center
Los Angeles, California, United States - University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States - NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, United States - (and 11 more...)
|
131 |
NCT00492778 |
Recruiting |
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer |
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- (and 3 more...)
|
- Radiation: 3-Dimensional Conformal Radiation Therapy
- Drug: Cisplatin
- Radiation: Intensity-Modulated Radiation Therapy
- Radiation: Internal Radiation Therapy
|
Interventional |
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Duration of progression-free survival
- Duration of overall survival
- Incidence of adverse effects graded by CTCAE version 3.0
- Prognostic significance of tumor size, tumor location (vaginal only vs. all others) and histology
|
164 |
Female |
Child, Adult, Senior |
NCT00492778 |
GOG-0238 NCI-2009-00603 CDR0000550975 U10CA180868 U10CA027469 |
|
February 25, 2008 |
July 1, 2022 |
|
June 27, 2007 |
February 16, 2018 |
|
- Sutter Auburn Faith Hospital
Auburn, California, United States - Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, United States - Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States - (and 437 more...)
|
132 |
NCT01010126 |
Completed |
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer |
- Adult Hepatocellular Carcinoma
- Advanced Adult Hepatocellular Carcinoma
- Endometrial Serous Adenocarcinoma
- (and 42 more...)
|
- Biological: Bevacizumab
- Drug: Temsirolimus
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival rate, defined as the proportion of efficacy-evaluable patients on study without documentation of disease progression 6 months from registration
- Tumor response rate defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to the RECIST criteria divided by the total number of efficacy evaluable patients enrolled on study
- Duration of response
- (and 4 more...)
|
252 |
All |
18 Years and older (Adult, Senior) |
NCT01010126 |
NCI-2012-02086 NCI-2011-02504 MC0845 CDR0000653790 NCI-2012-01049 8233 N01CM00032 N01CM00038 N01CM00039 N01CM00070 N01CM00071 N01CM00099 N01CM00100 N01CM62201 N01CM62203 N01CM62204 N01CM62205 N01CM62206 N01CM62207 N01CM62208 N01CM62209 P30CA015083 P50CA102701 |
|
September 8, 2009 |
March 13, 2017 |
March 13, 2017 |
November 9, 2009 |
July 11, 2017 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Tower Cancer Research Foundation
Beverly Hills, California, United States - City of Hope Comprehensive Cancer Center
Duarte, California, United States - (and 58 more...)
|
133 |
NCT00575952 |
Completed |
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer |
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Mixed Adenocarcinoma
- (and 8 more...)
|
- Drug: Cisplatin
- Drug: Doxorubicin Hydrochloride
- Biological: Filgrastim
- (and 2 more...)
|
Interventional |
Phase 1 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of observed DLTs, defined as grade 3-4 hematologic or non-hematologic toxicity graded using CTCAE v3.0
- Maximum tolerated dose (MTD) of IP paclitaxel with fixed dose IV doxorubicin hydrochloride and IV cisplatin, determined according to dose-limiting toxicities (DLTs) graded using CTCAE v3.0
- MTD of IP paclitaxel with fixed dose IV doxorubicin hydrochloride and IP cisplatin, determined according to DLTs graded using CTCAE v3.0
|
27 |
Female |
Child, Adult, Senior |
NCT00575952 |
GOG-9920 NCI-2009-00623 CDR0000580419 U10CA180868 U10CA027469 |
|
January 17, 2008 |
July 16, 2016 |
July 16, 2016 |
December 18, 2007 |
August 24, 2017 |
|
- Hartford Hospital
Hartford, Connecticut, United States - The Hospital of Central Connecticut
New Britain, Connecticut, United States - University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States - (and 6 more...)
|
134 |
NCT00478426 |
Active, not recruiting |
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer |
- Endometrial Adenocarcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- (and 5 more...)
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate, defined as the rate of complete or partial response as defined by the Response Evaluation Criteria for Solid Tumors
- Incidence of adverse effects assessed by Common Terminology Criteria for Adverse Events version 3.0
- Incidence of prolonged stable disease (i.e., best response of stable disease that is maintained for at least 6 months)
- (and 2 more...)
|
30 |
Female |
18 Years and older (Adult, Senior) |
NCT00478426 |
NCI-2009-00210 PHL-062 CDR0000513153 7713 N01CM62201 N01CM62203 N01CM62209 |
|
April 30, 2007 |
October 31, 2017 |
October 31, 2017 |
May 24, 2007 |
October 25, 2017 |
|
- Tower Cancer Research Foundation
Beverly Hills, California, United States - City of Hope Comprehensive Cancer Center
Duarte, California, United States - USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States - (and 26 more...)
|
135 |
NCT00416455 |
Active, not recruiting Has Results |
Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer |
- Cervical Adenocarcinoma
- Cervical Adenosquamous Cell Carcinoma
- Cervical Small Cell Carcinoma
- (and 11 more...)
|
- Radiation: fludeoxyglucose F 18
- Procedure: positron emission tomography
- Procedure: computed tomography
- (and 4 more...)
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Percent of Patients That FDG-PET-CT Will Indicate Positive Among Those With Lymph Node Metastasis in Abdomen
- Percent of Patients That DCT Will Indicate Positive Among Those With Lymph Node Metastasis in Abdomen
- Percent of Patients That FDG-PET-CT Will Indicate Positive Among Those With Lymph Node Metastasis in Pelvis
- (and 8 more...)
|
384 |
Female |
18 Years and older (Adult, Senior) |
NCT00416455 |
NCI-2009-00600 CDR0000521453 ACRIN 6671 GOG-0233/ACRIN 6671 GOG-0233-ACRIN 6671 GOG-0233 U10CA180868 U10CA027469 |
|
September 2007 |
September 2014 |
|
December 28, 2006 |
January 2, 2017 |
December 14, 2015 |
- Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - University of California at Los Angeles Health System
Los Angeles, California, United States - Olive View-University of California Los Angeles Medical Center
Sylmar, California, United States - (and 30 more...)
|
136 |
NCT00006011 |
Completed Has Results |
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer |
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- (and 3 more...)
|
- Drug: Doxorubicin Hydrochloride
- Drug: Cisplatin
- Biological: Filgrastim
- (and 2 more...)
|
Interventional |
Phase 3 |
- Gynecologic Oncology Group
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation.
|
659 |
Female |
Child, Adult, Senior |
NCT00006011 |
GOG-0184 NCI-2012-02350 ECOG-G0184 RTOG-EN0130 CDR0000068020 U10CA027469 |
|
July 2000 |
March 2010 |
|
January 27, 2003 |
May 19, 2015 |
June 26, 2014 |
- Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
|
137 |
NCT00072176 |
Completed Has Results |
Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer |
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Cell Carcinoma
- Endometrial Clear Cell Carcinoma
- (and 7 more...)
|
- Drug: temsirolimus
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Clinical Response Rate
- Progression-free Survival (Tumor Progression)
|
62 |
Female |
18 Years and older (Adult, Senior) |
NCT00072176 |
NCI-2014-00649 I160 CAN-NCIC-IND160 IND.160 CDR0000335543 NCIC-160 |
|
May 2004 |
May 2009 |
August 2009 |
November 6, 2003 |
February 23, 2015 |
February 23, 2015 |
- National Cancer Institute of Canada Clinical Trials Group
Kingston, Ontario, Canada
|
138 |
NCT00004150 |
Completed |
High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer |
|
- Drug: fluorouracil
- Drug: leucovorin calcium
- Procedure: adjuvant therapy
|
Interventional |
Phase 3 |
- Robert Roessle Klinik
- European Organisation for Research and Treatment of Cancer - EORTC
- Federation Francophone de Cancerologie Digestive
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00004150 |
CDR0000067383 PETACC-2 EORTC-40963 FFCD-PETACC-2 GETTD-PETACC-2 |
|
March 1999 |
|
April 2007 |
January 27, 2003 |
November 6, 2013 |
|
- Ziekenhuis Network Antwerpen Middelheim
Antwerpen, Belgium - Institut Jules Bordet
Brussels, Belgium - Hopital Universitaire Erasme
Brussels, Belgium - (and 82 more...)
|
139 |
NCT00025467 |
Completed |
Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer |
- Endometrial Adenoacanthoma
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Cell Carcinoma
- (and 3 more...)
|
- Drug: thalidomide
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients alive and progression-free
- Frequency of adverse events assessed by CTC
- Progression-free survival
- (and 2 more...)
|
60 |
Female |
Child, Adult, Senior |
NCT00025467 |
NCI-2012-02420 GOG-0229-B U10CA027469 CDR0000068964 |
|
September 2001 |
July 2007 |
|
October 15, 2003 |
January 24, 2013 |
|
- Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
|
140 |
NCT01643460 |
Recruiting |
Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts |
- Pancreatic Cyst
- Pancreatic Intraductal Papillary-Mucinous Neoplasm
- Cystadenoma, Mucinous
- Papillary Mucinous Cystadenoma, Borderline Malignancy
|
- Procedure: 98% Ethanol & Paclitaxel injection
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
22 |
All |
18 Years and older (Adult, Senior) |
NCT01643460 |
0812-57 |
|
September 2009 |
January 2020 |
January 2022 |
July 18, 2012 |
April 10, 2018 |
|
- Indiana University Hospital
Indianapolis, Indiana, United States
|
141 |
NCT00002896 |
Unknown † |
Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer |
|
- Drug: chemotherapy
- Drug: fluorouracil
- Drug: leucovorin calcium
- (and 3 more...)
|
Interventional |
Phase 3 |
- European Institute of Oncology
- National Cancer Institute (NCI)
|
Other |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
774 |
All |
up to 75 Years (Child, Adult, Senior) |
NCT00002896 |
CDR0000065222 CNR-9604 EU-96047 |
|
September 1993 |
|
|
May 13, 2004 |
September 20, 2013 |
|
- Ospedale St. Santa Chiara
Pisa, Italy
|
142 |
NCT00004178 |
Completed |
Gene Therapy in Treating Patients With Cancer |
|
- Biological: therapeutic autologous lymphocytes
|
Interventional |
Phase 1 |
- Roger Williams Medical Center
- Beth Israel Deaconess Medical Center
|
Other |
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00004178 |
CDR0000067388 BIDMC-941101148 NEDH-941101148 NCI-V99-1577 |
|
April 1998 |
December 2000 |
December 2001 |
April 19, 2004 |
June 10, 2011 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
143 |
NCT00897039 |
Unknown † |
Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Other: flow cytometry
- Other: immunohistochemistry staining method
|
Observational |
|
- Southeastern Gynecologic Oncology
- National Cancer Institute (NCI)
|
Other |
|
- Correlation of a statistically significant discriminator of sensitivity with complete response rate
|
60 |
Female |
Child, Adult, Senior |
NCT00897039 |
CDR0000491440 SEG-20060042 SEG-IRB-1075624 |
|
March 2006 |
|
|
May 12, 2009 |
September 20, 2013 |
|
- Southeastern Gynecologic Oncology, LLP - Northside
Atlanta, Georgia, United States
|
144 |
NCT01666444 |
Active, not recruiting |
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
|
- Drug: pegylated liposomal doxorubicin (PLD)
- Drug: VTX-2337
- Drug: Placebo
|
Interventional |
Phase 2 |
- VentiRx Pharmaceuticals Inc.
- Gynecologic Oncology Group
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall survival (OS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone
- Progression-free survival (PFS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone using Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST).
- Frequency and severity of drug-related adverse events (AEs) of patients treated with VTX-2337 + PLD versus those treated with PLD alone.
|
290 |
Female |
18 Years and older (Adult, Senior) |
NCT01666444 |
GOG-3003 |
|
October 2012 |
October 2016 |
October 2016 |
August 16, 2012 |
July 22, 2016 |
|
- St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - Winthrop P. Rockefeller Cancer Institute - University of Arkansas
Little Rock, Arkansas, United States - Providence Saint Joseph Medical Center
Burbank, California, United States - (and 133 more...)
|
145 |
NCT00331422 |
Terminated Has Results |
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
|
- Drug: carboplatin
- Drug: paclitaxel
- Procedure: cytoreductive surgery
|
Interventional |
Phase 2 |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients Who Underwent Optimal Cytoreduction After Chemotherapy
- Patients' Overall Tumor Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST)
- Clinical Response Based on Serum Cancer Antigen 125 (CA-125) Concentration
- (and 3 more...)
|
7 |
Female |
18 Years and older (Adult, Senior) |
NCT00331422 |
2004LS070 UMN-0409M64006 UMN- WCC-40 |
|
October 2005 |
March 2008 |
March 2009 |
May 31, 2006 |
December 28, 2017 |
February 8, 2010 |
- University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
|
146 |
NCT00408590 |
Active, not recruiting Has Results |
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Biological: carcinoembryonic antigen-expressing measles virus
- Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter
- Genetic: reverse transcriptase-polymerase chain reaction
- Other: laboratory biomarker analysis
|
Interventional |
Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity
- Number of Responses (Complete and Partial, Stable and Progressive Disease)
- Change in CA-125 Levels From Baseline to Last Recorded Value (up to 18 Months)
- Time to Progression
|
37 |
Female |
18 Years to 120 Years (Adult, Senior) |
NCT00408590 |
CDR0000515008 P30CA015083 MC0117 1260-03 NCI-2009-01199 |
|
April 19, 2004 |
August 2012 |
December 2018 |
December 7, 2006 |
March 7, 2018 |
October 2, 2017 |
- Mayo Clinic
Rochester, Minnesota, United States
|
147 |
NCT00003880 |
Terminated |
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Biological: recombinant adenovirus-p53 SCH-58500
- Drug: carboplatin
- Drug: paclitaxel
|
Interventional |
Phase 2 Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
132 |
Female |
18 Years and older (Adult, Senior) |
NCT00003880 |
C98102 SPRI-C/I98-102 SPRI-C98-102 NCI-V99-1544 CDR0000067047 |
|
February 1999 |
August 2001 |
August 2001 |
April 23, 2004 |
April 16, 2015 |
|
|
148 |
NCT00904514 |
Completed |
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial |
|
- Genetic: gene expression analysis
- Genetic: microarray analysis
- Genetic: mutation analysis
- (and 4 more...)
|
Observational |
|
- National Institutes of Health Clinical Center (CC)
- National Cancer Institute (NCI)
|
NIH |
|
- Analyses of stored human samples, specimens, and data collected from patients previously enrolled in a terminated National Cancer Institute-Institutional Review Board clinical trial
- Correlation of plasma levels and pharmacokinetics with disease burden and presence of antibodies
- Correlation of tumor markers with disease burden
- Utility of tumor markers for following patients after treatment
|
241 |
All |
18 Years and older (Adult, Senior) |
NCT00904514 |
CDR0000573913 NCI-08-C-N013 P07268 |
|
October 2007 |
October 2007 |
October 2007 |
May 19, 2009 |
February 20, 2012 |
|
|
149 |
NCT00003380 |
Terminated |
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Drug: etoposide
- Drug: pegylated liposomal doxorubicin hydrochloride
|
Interventional |
Phase 1 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
Child, Adult, Senior |
NCT00003380 |
CDR0000066375 GOG-9704 |
|
May 1998 |
July 2002 |
|
August 16, 2004 |
June 10, 2013 |
|
- University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States - CCOP - Greater Phoenix
Phoenix, Arizona, United States - USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - (and 60 more...)
|
150 |
NCT00006235 |
Completed |
Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Drug: carboplatin
- Drug: pegylated liposomal doxorubicin hydrochloride
|
Interventional |
Phase 1 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
Child, Adult, Senior |
NCT00006235 |
CDR0000068160 GOG-9909 |
|
|
February 2006 |
|
June 22, 2004 |
July 9, 2013 |
|
|